Target Price | $101.06 |
Price | $68.28 |
Potential | 48.01% |
Number of Estimates | 17 |
17 Analysts have issued a price target Moderna 2025 . The average Moderna target price is $101.06. This is 48.01% higher than the current stock price. The highest price target is $238.00 248.56% , the lowest is $46.00 32.63% . | |
A rating was issued by 26 analysts: 8 Analysts recommend Moderna to buy, 15 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Moderna stock has an average upside potential 2025 of 48.01% . Most analysts recommend the Moderna stock at Hold. |
20 Analysts have issued a sales forecast Moderna 2024 . The average Moderna sales estimate is $3.2b . This is 35.61% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $3.5b 29.89% , the lowest is $2.8b 43.89% .
This results in the following potential growth metrics:
2023 | $6.8b | 64.21% |
---|---|---|
2024 | $3.2b | 52.53% |
2025 | $3.4b | 4.75% |
2026 | $4.4b | 28.83% |
2027 | $6.2b | 42.08% |
2028 | $8.7b | 39.83% |
9 Analysts have issued an Moderna EBITDA forecast 2024. The average Moderna EBITDA estimate is $-3.7b . This is 10.86% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $-3.1b 25.04% , the lowest is $-4.2b 2.02% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $-3.6b | 137.72% |
---|---|---|
2024 | $-3.7b | 1.17% |
2025 | $-3.0b | 19.00% |
2026 | $-2.2b | 27.49% |
2027 | $-494m | 77.06% |
2023 | -53.01% | 205.37% |
---|---|---|
2024 | -112.99% | 113.14% |
2025 | -87.37% | 22.67% |
2026 | -49.18% | 43.71% |
2027 | -7.94% | 83.86% |
13 Moderna Analysts have issued a net profit forecast 2024. The average Moderna net profit estimate is $-3.7b . This is 38.16% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $-3.2b 46.22% , the lowest is $-4.0b 31.92% .
This results in the following potential growth metrics and future Net Margins:
2023 | $-4.7b | 161.39% |
---|---|---|
2024 | $-3.7b | 22.93% |
2025 | $-3.1b | 14.68% |
2026 | $-2.3b | 26.85% |
2027 | $-1.3b | 44.03% |
2028 | $-1.1b | 10.88% |
2023 | -69.28% | 271.51% |
---|---|---|
2024 | -112.49% | 62.38% |
2025 | -91.62% | 18.55% |
2026 | -52.02% | 43.22% |
2027 | -20.49% | 60.61% |
2028 | -13.06% | 36.26% |
13 Analysts have issued a Moderna forecast for earnings per share. The average Moderna <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $-9.51 . This is 38.17% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $-8.27 46.23% , the lowest is $-10.47 31.92% .
This results in the following potential growth metrics and future valuations:
2023 | $-12.34 | 161.39% |
---|---|---|
2024 | $-9.51 | 22.93% |
2025 | $-8.11 | 14.72% |
2026 | $-5.93 | 26.88% |
2027 | $-3.32 | 44.01% |
2028 | $-2.96 | 10.84% |
Current | -4.44 | 116.81% |
---|---|---|
2024 | -7.18 | 61.71% |
2025 | -8.42 | 17.27% |
2026 | -11.50 | 36.58% |
2027 | -20.56 | 78.78% |
2028 | -23.07 | 12.21% |
Based on analysts' sales estimates for 2024, the Moderna stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 5.86 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 8.08 .
This results in the following potential growth metrics and future valuations:
Current | 3.77 | 18.18% |
---|---|---|
2024 | 5.86 | 55.46% |
2025 | 5.60 | 4.53% |
2026 | 4.34 | 22.38% |
2027 | 3.06 | 29.62% |
2028 | 2.19 | 28.48% |
Current | 5.21 | 34.08% |
---|---|---|
2024 | 8.08 | 55.30% |
2025 | 7.72 | 4.53% |
2026 | 5.99 | 22.38% |
2027 | 4.22 | 29.62% |
2028 | 3.02 | 28.49% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.